February 28, 2018 / 10:03 PM / 10 months ago

BRIEF-Asterias Provides Update For Its AST-OPC1 Phase 1/2A Clinical Trial

Feb 28 (Reuters) - Asterias Biotherapeutics Inc:

* ASTERIAS PROVIDES UPDATE FOR ITS AST-OPC1 PHASE 1/2A CLINICAL TRIAL IN SEVERE SPINAL CORD INJURY

* ASTERIAS BIOTHERAPEUTICS INC - ‍RESULTS TO DATE SHOW AST-OPC1’S FAVORABLE SAFETY PROFILE, POTENTIAL FOR CELL ENGRAFTMENT AND IMPROVED MOTOR FUNCTION​

* ASTERIAS BIOTHERAPEUTICS INC - ‍MULTIPLE ADDITIONAL DATA READOUTS FROM SCISTAR STUDY EXPECTED IN 2018 INTO Q1 OF 2019​

* ASTERIAS BIOTHERAPEUTICS INC - ‍THERE HAVE BEEN NO SERIOUS, UNEXPECTED, ADVERSE EVENTS RELATED TO AST-OPC1, INJECTION PROCEDURE​

* ASTERIAS BIOTHERAPEUTICS INC - ‍TO DATE, THERE HAVE BEEN NO SERIOUS ADVERSE EVENTS RELATED TO AST-OPC1 CELLS​ Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below